- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Juvenile idiopathic arthritis
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 904KB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 156KB)
Tofacitinib – March 2023
Tofacitinib (JIA): Tablet 5 mg, Oral liquid 1 mg per mL, 240 mL; Xeljanz®
Last updated
30 May 2025